Corindus Vascular Robotics Stock Price, News & Analysis (NYSEAMERICAN:CVRS)

$1.03 0.02 (1.98 %)
(As of 01/19/2018 01:58 PM ET)
Previous Close$1.01
Today's Range$1.00 - $1.05
52-Week Range$0.40 - $2.25
Volume245,300 shs
Average Volume302,792 shs
Market Capitalization$194.36 million
P/E Ratio-4.29
Dividend YieldN/A
Beta19.49

About Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Corindus Vascular Robotics logoCorindus Vascular Robotics, Inc. is engaged in robotic-assisted vascular interventions. The Company's CorPath System is a medical device that brings robotic-assisted precision to radial, coronary and peripheral procedures. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System it brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. It operates through the development, marketing and sales of robotic-assisted vascular interventions segment. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected, ergonomic interventional cockpit. The CorPath System consists of two components: a bedside unit and an interventional cockpit.

Receive CVRS News and Ratings via Email

Sign-up to receive the latest news and ratings for CVRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorHealthcare
SymbolNYSEAMERICAN:CVRS
CUSIPN/A
Phone+1-508-6533335

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio-4.29166666666667
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS($0.24)
Net IncomeN/A
Net Margins-323.84%
Return on Equity-110.93%
Return on Assets-88.11%

Miscellaneous

EmployeesN/A
Outstanding Shares188,700,000

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Frequently Asked Questions

What is Corindus Vascular Robotics' stock symbol?

Corindus Vascular Robotics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVRS."

How were Corindus Vascular Robotics' earnings last quarter?

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) issued its quarterly earnings data on Tuesday, November, 7th. The medical equipment provider reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The medical equipment provider had revenue of $2.43 million for the quarter, compared to the consensus estimate of $3.60 million. Corindus Vascular Robotics had a negative return on equity of 110.93% and a negative net margin of 323.84%. View Corindus Vascular Robotics' Earnings History.

Where is Corindus Vascular Robotics' stock going? Where will Corindus Vascular Robotics' stock price be in 2018?

2 brokerages have issued 12-month price targets for Corindus Vascular Robotics' shares. Their predictions range from $3.00 to $3.00. On average, they anticipate Corindus Vascular Robotics' share price to reach $3.00 in the next year. View Analyst Ratings for Corindus Vascular Robotics.

Are investors shorting Corindus Vascular Robotics?

Corindus Vascular Robotics saw a decline in short interest in December. As of December 29th, there was short interest totalling 11,613,722 shares, a decline of 2.8% from the December 15th total of 11,945,130 shares. Based on an average daily volume of 542,589 shares, the days-to-cover ratio is currently 21.4 days. Approximately 12.6% of the company's shares are sold short.

Who are some of Corindus Vascular Robotics' key competitors?

Who are Corindus Vascular Robotics' key executives?

Corindus Vascular Robotics' management team includes the folowing people:

  • Jeffrey C. Lightcap, Independent Chairman of the Board (Age 57)
  • Mark J. Toland, President, Chief Executive Officer, Director (Age 46)
  • David W. Long, Chief Financial Officer, Senior Vice President, Treasurer, Secretary (Age 46)
  • John K. Bakewell, Director (Age 55)
  • Louis A Cannon M.D., Director
  • Gerard Winkels, Director (Age 59)
  • Hillel Bachrach, Independent Director (Age 70)
  • Jeffrey Gold, Independent Director (Age 68)

Who owns Corindus Vascular Robotics stock?

Corindus Vascular Robotics' stock is owned by many different of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.11%). Company insiders that own Corindus Vascular Robotics stock include Healthcor Management, LP, Jeffrey Gold, Louis A Cannon and Philips Nv Koninklijke. View Institutional Ownership Trends for Corindus Vascular Robotics.

Who sold Corindus Vascular Robotics stock? Who is selling Corindus Vascular Robotics stock?

Corindus Vascular Robotics' stock was sold by a variety of institutional investors in the last quarter, including Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Corindus Vascular Robotics.

How do I buy Corindus Vascular Robotics stock?

Shares of Corindus Vascular Robotics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Corindus Vascular Robotics' stock price today?

One share of Corindus Vascular Robotics stock can currently be purchased for approximately $1.03.

How big of a company is Corindus Vascular Robotics?

Corindus Vascular Robotics has a market capitalization of $194.36 million.

How can I contact Corindus Vascular Robotics?

Corindus Vascular Robotics' mailing address is 309 Waverley Oaks Rd Ste 105, WALTHAM, MA 02452-8451, United States. The medical equipment provider can be reached via phone at +1-508-6533335.


MarketBeat Community Rating for Corindus Vascular Robotics (CVRS)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  142 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about Corindus Vascular Robotics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.00$3.00$3.00$3.00
Price Target Upside: 80.72% upside80.72% upside80.72% upside147.93% upside

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Consensus Price Target History

Price Target History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
8/9/2017CowenSet Price TargetBuy$3.00View Rating Details
5/15/2017B. RileyReiterated RatingBuy$3.00View Rating Details
4/20/2016Sterne Agee CRTReiterated RatingBuy$3.00View Rating Details
1/19/2016Stifel NicolausLower Price TargetBuy$6.00 -> $4.00View Rating Details
(Data available from 1/19/2016 forward)

Earnings

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Earnings History and Estimates Chart

Earnings by Quarter for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Corindus Vascular Robotics (NYSEAMERICAN CVRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.05)($0.04)$3.60 million$2.43 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.05)($0.04)$3.10 million$2.26 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.05)($0.07)$1.59 million$0.78 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.07)($0.08)$0.73 million$0.54 millionViewN/AView Earnings Details
11/8/2016Q316($0.06)($0.07)$1.27 million$0.69 millionViewListenView Earnings Details
8/4/2016Q2 2016($0.06)($0.06)ViewN/AView Earnings Details
5/5/2016Q1 2016($0.06)($0.06)ViewN/AView Earnings Details
3/8/2016Q415($0.05)($0.06)$0.62 million$0.83 millionViewN/AView Earnings Details
11/12/2015Q315($0.06)($0.06)$0.70 million$0.21 millionViewListenView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Corindus Vascular Robotics (NYSEAMERICAN CVRS) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)
Institutional Ownership by Quarter for Corindus Vascular Robotics (NYSEAMERICAN:CVRS)

Corindus Vascular Robotics (NYSEAMERICAN CVRS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017Louis A CannonDirectorBuy23,801$0.81$19,278.81View SEC Filing  
3/22/2017Louis A CannonDirectorBuy27,000$1.30$35,100.00View SEC Filing  
2/28/2017Healthcor Management, L.P.Major ShareholderBuy7,557,436$0.66$4,987,907.76View SEC Filing  
11/25/2016Jeffrey GoldDirectorBuy10,000$0.76$7,600.009,098View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Corindus Vascular Robotics (NYSEAMERICAN CVRS) News Headlines

Source:
DateHeadline
Corindus Vascular Robotics (CVRS) Lowered to "Hold" at Zacks Investment ResearchCorindus Vascular Robotics (CVRS) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 12 at 8:50 PM
Corindus Vascular Robotics Inc (CVRS) Short Interest UpdateCorindus Vascular Robotics Inc (CVRS) Short Interest Update
www.americanbankingnews.com - January 11 at 2:36 AM
Detailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Athersys, Repros Therapeutics, GCP Applied Technologies, IDACORP, Mobile Mini, and Corindus Vascular Robotics — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - January 4 at 8:53 AM
Corindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary ... - Business Wire (press release)Corindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary ... - Business Wire (press release)
www.businesswire.com - January 2 at 5:47 PM
Corindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary Interventions Remote Treatment CapabilitiesCorindus to Participate with Mayo Clinic in Preclinical Study of Remote Control Robotics for Percutaneous Coronary Interventions Remote Treatment Capabilities
finance.yahoo.com - January 2 at 5:47 PM
ETFs with exposure to Corindus Vascular Robotics, Inc. : December 28, 2017ETFs with exposure to Corindus Vascular Robotics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:34 PM
Corindus Announces First Commercial Installation of CorPath - Business Wire (press release)Corindus Announces First Commercial Installation of CorPath - Business Wire (press release)
www.businesswire.com - December 15 at 6:34 PM
Corindus Vascular Robotics (CVRS) Reports First Commercial Installation of CorPath GRX System Outside of US - StreetInsider.comCorindus Vascular Robotics (CVRS) Reports First Commercial Installation of CorPath GRX System Outside of US - StreetInsider.com
www.streetinsider.com - December 15 at 6:34 PM
Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
finance.yahoo.com - December 14 at 8:57 AM
ETFs with exposure to Corindus Vascular Robotics, Inc. : December 11, 2017ETFs with exposure to Corindus Vascular Robotics, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:59 PM
Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for PhysiciansCorindus Partners with Houston Methodist DeBakey Heart & Vascular Center to Launch Premier Robotic Training Site for Physicians
finance.yahoo.com - December 1 at 4:15 PM
ETFs with exposure to Corindus Vascular Robotics, Inc. : November 30, 2017ETFs with exposure to Corindus Vascular Robotics, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:48 PM
Short Interest in Corindus Vascular Robotics Inc (CVRS) Declines By 3.7%Short Interest in Corindus Vascular Robotics Inc (CVRS) Declines By 3.7%
www.americanbankingnews.com - November 27 at 9:56 PM
ETFs with exposure to Corindus Vascular Robotics, Inc. : November 20, 2017ETFs with exposure to Corindus Vascular Robotics, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 6:42 PM

SEC Filings

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Corindus Vascular Robotics (NYSEAMERICAN CVRS) Stock Chart for Friday, January, 19, 2018

Loading chart…

This page was last updated on 1/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.